Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dupilumab · 1 trial · 2 indications
Phase 2: Safety of treatment, defined as the frequency and percentage of DLTs, from start of treatment up to 30 days post the last administration of study drug (dupilumab).
| Arm | Type | Description |
|---|---|---|
| Dupilumab and toripalimab | EXPERIMENTAL | Participants will receive the combination of Dupilumab and Toripalimab |
| Name | Type | Description |
|---|---|---|
| Dupilumab | DRUG | Dupilumab is commercially sourced, and provided as 300mg pre-filled syringes, though packaging may vary. Dupilumab 600mg SC on Day 1 and 300mg SC on Day 15 (+/-2 days). |
| Toripalimab | DRUG | Toripalimab will be supplied as a liquid in sterile, single-use vials that will display the product lot number on the label. Each vial contains 240 mg/6 mL (40 mg/mL) solution. Toripalimab 240mg IV over 60 minutes or longer on Day 1 before planned surgery. |
INCLUSION CRITERIA: Histological diagnosis of non-MSI-H/pMMR CRC • Subjects who have biology-proven non-MSI-H/pMMR CRC and with radiographic findings suggestive of liver metastases may be eligible. Resectable liver metastases including: * synchronous liver metastases (present at the time of diag...
Top 20 of 77 competitors
Dupilumab is being studied as a neoadjuvant treatment for patients with metastatic colorectal cancer who have resectable liver metastases. It is administered in combination with toripalimab in a Phase 1 clinical trial. The study is currently recruiting participants in the United States.
Coherus Oncology, Inc. (NASDAQ: CHRS) is developing Dupilumab for metastatic colorectal cancer. The company is conducting a Phase 1 clinical trial of dupilumab in combination with toripalimab for patients with resectable liver metastases from colorectal cancer.
Dupilumab is in Phase 1 clinical development for metastatic colorectal cancer. It is being evaluated in an open-label, uncontrolled trial that is currently recruiting patients. The drug is investigational and has not been approved for this indication.
Dupilumab is being studied in a Phase 1 trial with the identifier NCT07277322, titled 'Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases.' The trial is recruiting 24 participants in the United States and is not yet completed.
Dupilumab is a monoclonal antibody, classified as a -mab (antibody) therapeutic. It is being tested in combination with toripalimab, another antibody, for the treatment of metastatic colorectal cancer with liver metastases.